Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 diabetes. Whether clinically important responses and adverse events (AEs) are dependent on the route of administration has not been determined. We demonstrate that nearly identical exposure-response pharmacodyna...

Descripción completa

Detalles Bibliográficos
Autores principales: Overgaard, Rune V., Hertz, Christin L., Ingwersen, Steen H., Navarria, Andrea, Drucker, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484505/
https://www.ncbi.nlm.nih.gov/pubmed/34622228
http://dx.doi.org/10.1016/j.xcrm.2021.100387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484505/
https://www.ncbi.nlm.nih.gov/pubmed/34622228
http://dx.doi.org/10.1016/j.xcrm.2021.100387

Ejemplares similares